Spots Global Cancer Trial Database for bromodomain
Every month we try and update this database with for bromodomain cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT02705469 | Metastatic Cast... | ZEN003694 | 18 Years - | Zenith Epigenetics | |
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | NCT03936465 | Solid Tumor, Ch... Lymphoma Brain Tumor, Pe... | BMS-986158 BMS-986378 | 1 Year - 21 Years | Dana-Farber Cancer Institute | |
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | NCT04986423 | Metastatic Cast... | ZEN003694 Enzalutamide | 18 Years - | Zenith Epigenetics | |
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | NCT04986423 | Metastatic Cast... | ZEN003694 Enzalutamide | 18 Years - | Zenith Epigenetics |